Safety Study of Topical Human FGF-1 for Wound Healing

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Phage Pharmaceuticals, Inc..
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Phage Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00916292
First received: June 5, 2009
Last updated: March 9, 2012
Last verified: March 2012

June 5, 2009
March 9, 2012
November 2012
September 2013   (final data collection date for primary outcome measure)
Safety and tolerability of a single dose of FGF-1 topically administered in normal volunteers given an artificial dermal wound [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00916292 on ClinicalTrials.gov Archive Site
Serum levels of FGF-1 after topical administration [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Safety Study of Topical Human FGF-1 for Wound Healing
A Phase 1a, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Normal Volunteers Given Punch Skin Biopsies

The purpose of the study is to see if FGF-1 is safe when applied topically to the surface of a wound.

Dermal ulcers pose a significant healthcare problem in the United States, ultimately affecting 10-15% of the approximately 20 million patients with diabetes and a similar number of patients with chronic venous insufficiency. Dermal leg and foot ulcers can result from compromised arterial inflow, microvascular perfusion or venous outflow which can lead to amputation unless vascular perfusion is improved. FGF-1 for topical administration offers the possibility of improved microvascular perfusion by promoting the formation of new blood vessels in the wound bed resulting in enhanced development of granulation tissue and accelerated healing.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetic Foot Ulcers
  • Drug: FGF-1 141
    Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
  • Drug: FGF-1 141
    Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
  • Experimental: Low dose
    Four subjects will receive low dose FGF-1
    Intervention: Drug: FGF-1 141
  • Experimental: High Dose
    Four subjects will receive high dose FGF-1
    Intervention: Drug: FGF-1 141
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
8
September 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Sign an informed consent form prior to the initiation of any study procedures. Subjects must be competent to give written informed consent.
  2. Age must be between 18 to 75 years of age.
  3. Female subject must be post-menopausal or sterilized, or if she is of childbearing potential, she is not breast feeding, and her serum pregnancy test is negative.
  4. Subjects must be willing to change their wound dressings daily and demonstrate to study personnel the ability to follow the dressing care instructions indicated in the Appendix. Subjects considered eligible to enter the study must sign an informed consent form prior to the initiation of any study procedures. In the event that the subject must be withdrawn and is re-screened for study participation at a later date, a new informed consent form must be signed. Subjects must be competent to give written informed consent.

Exclusion Criteria:

  1. Subjects receiving radiation therapy, corticosteroids, immunosuppressive agents or chemotherapy.
  2. Subjects who, at study entry, are taking systemic antibiotics.
  3. Subjects who are immunosuppressed.
  4. Subjects experiencing bacterial or viral infection or who may otherwise be febrile.
  5. Past history or current presence of any type of cancer (except past history of basal cell carcinoma that is not on the limb being treated). Subjects with existing BCC will be excluded from the study.
  6. Life expectancy of less than 1 year.
  7. Active alcohol or drug abuse within 6 months prior to study entry.
  8. Screening liver function tests of more than 2.0 times the upper limit of normal.
  9. Serum creatinine of ≥ 2.5 mg/dl.
  10. Hemoglobin A1c (HgbA1c) of >10%.
  11. Exposure to any other investigational drugs or devices or participation in any other investigational studies within 30 days prior to study entry.
  12. Any other medical, social, or geographical factor that would make it unlikely that the subject will comply with study procedures (e.g., alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or a history of non-compliance).
Both
18 Years to 75 Years
Yes
Not Provided
United States
 
NCT00916292
Phage-W2009-01-1a
No
Phage Pharmaceuticals, Inc.
Phage Pharmaceuticals, Inc.
Not Provided
Principal Investigator: Shawn Searle, MD Dedicated Phase I
Phage Pharmaceuticals, Inc.
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP